Non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised,placebo-controlled,observer-blinded,proof-of-concept, phase 2b trial. Lancet Respir Med 2022.The vaccine efficacy in reducing the yearly rate of moderate or severe AECOPD has been corrected to -2·26% in the abstract This correction has been made to the online version as of June 30, 2022.The COVID-19 continuum of illness. Lancet Respir Med 2022.This correction has been made to the online version as of June 29, 2022.

2022-05-01·The Lancet Respiratory Medicine1区 · 医学

Non-typeable Haemophilus influenzae–Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial

1区 · 医学

Article

作者: Wilkinson, Tom M A ; Boscia III, Joseph ; De-Soyza, Anthony ; Testa, Marco ; Narejos Pérez, Silvia ; Llorca Martínez, Eleuterio ; Papi, Alberto ; Janssens, Wim ; Di Maro, Gennaro ; Tannous, Ziad ; Maltais, François ; Saralaya, Dinesh ; Dussart, Luc ; Schoonbroodt, Sonia ; Lattanzi, Maria ; Sigal, Barry ; Janssens, Eduard ; Kerwin, Edward ; Puente-Maestu, Luis ; Moraschini, Luca ; Eich, Andreas ; Boyer, Laurent ; Choudhury, Gourab ; Bourdin, Arnaud ; Fogarty, Charles ; Couturaud, Francis ; Ferguson, Murdo ; Echave-Sustaeta, José Maria ; Brusselle, Guy ; Leys, Mathias ; Fitzgerald, Mark ; Illies, Gabriele ; Downey, Herman Jackson ; Centanni, Stefano ; Kunz, Craig ; Erb, David ; Ludwig-Sengpiel, Andrea ; Pek, Bonavuth ; Terns Riera, Manuel ; Chinsky, Kenneth ; Pérez Vera, Mercè ; Mayers, Irvin ; Dunn, Leonard ; Pascual-Guardia, Sergi ; Andreas, Stefan ; Watz, Henrik ; Pomari, Carlo ; Poling, Terry ; Arora, Ashwani K ; Spangenthal, Selwyn ; Tasciotti, Annaelisa ; McNeil, Shelly ; Wilkinson, Tom MA ; Sellman, Richard ; Anderson, William ; Southard, John ; Blasi, Francesco ; Casula, Daniela ; Corhay, Jean-Louis

BACKGROUNDAcute exacerbations of chronic obstructive pulmonary disease (AECOPD) are associated with changes in the sputum microbiome, including an increased prevalence of pathogenic bacteria. Vaccination against the most frequent bacteria identified in AECOPD might reduce exacerbation frequency. We assessed the efficacy, safety, and immunogenicity of a candidate vaccine containing surface proteins from non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) in patients with COPD.METHODSThis multicentre, randomised, observer-blinded, placebo-controlled, proof-of-concept, phase 2b trial recruited patients with stable COPD, moderate-to-very severe airflow limitation (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage 2, 3, or 4), at 67 clinical sites in Belgium, Canada, France, Germany, Italy, Spain, UK, and USA. Eligible patients were aged 40-80 years and had a history of at least one moderate or severe exacerbation in the previous year. Patients were allocated (1:1) using a minimisation algorithm to receive two intramuscular injections of NTHi-Mcat vaccine or placebo 60 days apart, in addition to standard care. The allocation algorithm considered age category, number of previous exacerbations, COPD severity at study entry, and country as minimisation factors, to guarantee treatment balance within each factor. Vaccine recipients and those responsible for evaluating study endpoints were masked to group allocation. In the analysis of efficacy, the primary outcome was the rate of any moderate or severe AECOPD occurring within a 1-year period, starting 1 month after the second dose in patients who received two vaccine doses (modified total vaccinated cohort). Safety was assessed in the total vaccinated cohort. The trial is registered with ClinicalTrials.gov, number NCT03281876, and is complete.FINDINGSBetween Nov 27, 2017, and Nov 30, 2018, 606 adults were enrolled and included in the total vaccinated cohort (304 in the NTHi-Mcat vaccine group, 302 in the placebo group); 571 received two doses and were included in the primary efficacy analysis (279 in the NTHi-Mcat vaccine group, 292 in the placebo group). 23 participants dropped-out in the NTHi-Mcat vaccine group and 39 in the placebo group; this included 4 patients in the NTHi-Mcat vaccine group and 15 in the placebo group who withdrew from the study because of an adverse event. The primary analysis included 340 exacerbations (in follow-up time 102 123 days) in the NTHi-Mcat vaccine group and 333 (in 104 443 days) in the placebo group, with a yearly rate of moderate or severe AECOPD of 1·22 in the NTHi-Mcat vaccine group and 1·17 in the placebo group, with vaccine efficacy in reducing the yearly rate of moderate or severe AECOPD estimated to be zero (vaccine efficacy point estimate 2·26% [87% CI -18·27 to 11·58]; p=0·82). Solicited local adverse events were more frequent in the NTHi-Mcat vaccine group (216 [72%] of 301 patients) than with placebo (34 [11%] of 299 patients), and the frequency of solicited general adverse events was similar between groups (239 [79%] of 301 vs 235 [79%] of 299 patients). There was one death in the NTHi-Mcat vaccine group (acute respiratory failure, not related to vaccination) and ten in the placebo group (seven due in part to COPD or respiratory failure). There were 158 serious adverse events (89 [29%] of 304 patients) in the NTHi-Mcat vaccine group, not related to vaccination, and 214 (99 [33%] of 302 patients) in the placebo group.INTERPRETATIONNTHi-Mcat vaccine administered to patients with COPD did not show efficacy in reducing the yearly rate of moderate or severe exacerbations. No safety concerns were identified.FUNDINGGlaxoSmithKline Biologicals SA.

2021-12-01·Vaccine: X

Long-term immunogenicity and safety of a non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine: 4-year follow-up of a phase 1 multicentre trial

Article

作者: Tasciotti, Annaelisa ; Dozot, Marie ; Casula, Daniela ; Vandermeulen, Corinne ; Riccucci, Daniele ; Annaratone, Margherita ; De Smedt, Philippe ; Arora, Ashwani Kumar ; Di Maro, Gennaro ; Leroux-Roels, Geert

A multicomponent vaccine has been developed to reduce the frequency of acute exacerbations of COPD associated with non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) infections, containing NTHi (PD and PE-PilA) and Mcat (UspA2) surface proteins. In a randomised, observer-blind, placebo-controlled study with two steps (NCT02547974), the investigational vaccine had good immunogenicity and no safety concerns were identified. In step 2, 90 adults aged 50-71 years with smoking history received two doses 60 days apart of one of two AS01_E-adjuvanted formulations containing 10 µg of each antigen (10-10-AS01) or 10 µg NTHi antigens and 3.3 µg UspA2 (10-3-AS01), or placebo. Long-term persistence of antigen-specific humoral antibodies was assessed in 81 participants during 3 years of follow-up after the initial 14-month study (NCT03201211). Antigen-specific antibody concentrations were measured in blood samples taken every 6 months. Safety monitoring evaluated serious adverse events (SAEs) and potential immune-mediated disease (pIMD). Immune responses against NTHi antigens persisted up to 4 years post-vaccination. For PD, PE and PilA, at each follow-up time point, adjusted antibody geometric mean concentrations (GMCs) were higher (non-overlapping 95% confidence intervals [CIs]) in the vaccine groups versus placebo and versus pre-vaccination. Antibody GMC point estimates were higher with 10-3-AS01 than with 10-10-AS01. For UspA2, 95% CIs included 1 for GMC ratios of 10-10-AS01 or 10-3-AS01 to placebo at each time point. During follow-up, SAEs were reported in nine (11.1%) participants, one of which was fatal (lung cancer, 607 days after second 10-10-AS01 dose). One non-serious pIMD, trigeminal neuralgia, was reported 771 days after second 10-3-AS01 dose. The SAEs and pIMD were considered not related to vaccination. Immune responses against NTHi antigens persisted for 4 years after two-dose vaccination with the investigational NTHi-Mcat vaccine. There was no persistent response against the Mcat antigen. No safety concerns were identified during the long-term follow-up.

100 项与 ACE-810 相关的药物交易

登录后查看更多信息